Emcure Pharmaceuticals Launches Injectable To Treat Iron Deficiency In India

Emcure Pharmaceuticals Limited (EPL) announced the launch of Orofer FCM 750, a new parenteral iron brand containing Ferric carboxymaltose (FCM). The new dosage variant is intended to provide a more effective and convenient option for patients with iron deficiency and iron deficiency anaemia (IDA), according to the pharmaceutical company. Emcure Pharmaceuticals Limited (EPL) this week announced the launch of Orofer FCM 750, a new extension of its parenteral iron brand containing Ferric carboxymaltose (FCM).

According to the pharmaceutical company, the new dosage variant is intended to provide a more effective and convenient option for patients suffering from iron deficiency and iron deficiency anaemia (IDA). Indian studies using FCM for the treatment of IDA in pregnancy have indicated that most patients have mean Haemoglobin <10 g/dl. They may require FCM 1500 mg at body weight between 35-70 kgs.

A single dose of FCM up to 750 mg of iron can be infused in a short time frame of 15 minutes diluted in 250 ml of normal saline. According to Indian studies using FCM to treat IDA in pregnancy, the majority of patients have a mean haemoglobin of 10 g/dl. They may require FCM 1500 mg if their body weight is between 35 and 70 kg. A single dose of FCM containing up to 750 mg of iron can be infused in 15 minutes after being diluted in 250 ml of normal saline. In April 2018, the Intensified National Iron Plus Initiative (I-NIPI) operational guidelines for the “Anemia Mukt Bharat” Programme recommended FCM as the first-line treatment for severe and selected cases of mild-to-moderate anemia in pregnant women in India.

According to the company, FCM, a unique iron complex consists of a ferric hydroxide core stabilized by a carbohydrate shell, enabling controlled iron delivery to target tissues. FCM can elevate serum ferritin and Hemoglobin levels and provide better compliance as compared to oral iron and iron sucrose therapy. Emcure Pharmaceuticals Limited aims to address the unmet medical needs of patients suffering from IDA in India by providing a reliable and convenient treatment option, it claimed.